Nuformix hoping to "initiate discussions with major pharma" in 2023 | News Direct

Nuformix hoping to "initiate discussions with major pharma" in 2023

Nuformix PLC
Digital Asset Direct by Nuformix PLC
Download PDF Download multimedia

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | December 20, 2022 08:00 AM Eastern Standard Time

Nuformix PLC (LSE:NFX) executive director Dr Dan Gooding speaks to Proactive shortly after releasing an update on the company's NXP004 programme, aimed at developing novel forms of AstraZeneca’s Olaparib (Lynparza) cancer drug. Gooding reveals what investors can expect from Nuformix in 2023, saying that his aspiration is for data from the NXP002 programme to be supportive of the company "initiating discussions with major pharma."

 

Contact Details

 

Proactive

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.